Track topics on Twitter Track topics that are important to you
Here are the most relevant search results for "Galectin Therapeutics" found in our extensive news archives from over 250 global news sources.
In addition to our news stories we have dozens of PubMed Articles about Galectin Therapeutics for you to read. Along with our medical data and news we also list Galectin Therapeutics Clinical Trials, which are updated daily. BioPortfolio also has a large database of Galectin Therapeutics Companies for you to search.
Galectin Therapeutics Inc. announced enrollment is complete for its phase 2 NASH-FX trial investigating GR-MD-02, a complex carbohydrate drug that targets galectin-3, for the treatment of nonalcoholic steatohepatitis and advanced fibrosis.The study, which will be led by Stephen A. Harrison, MD, FACP, FAASLD, professor of medicine at the Uniformed Services University of the Health Sciences, San Ant...
Galectin Therapeutics has completed enrollment in its phase 2 clinical trial of GR-MD-02 in patients with non-alcoholic steatohepatitis (NASH) with advanced fibrosis (stage 3).
Galectin Therapeutics (NASDAQ:GALT) has announced the election of Dr. Marc Rubin as chairman, succeeding James Czirr, who helped found the company in 2000. Mr. Czirr will continue as a director. Dr. Rubin is a leading bioscience industry executive with more than 25 years of senior management and board experience in the development and commercialization of […]
Galectin-3 is a unique member of chimera type galectins and is involved in a large number of disease processes and...
* Completion of enrollment in phase 2 clinical trial with GR-MD-02 in patients with NASH with advanced fibrosis
WALTHAM, Mass., Dec. 23, 2015 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (OTCQB:BGMD) today announced that it has submitted to the FDA a notice of withdrawal of its 510(k) premarket notification filing with the US Food and Drug Administration (“FDA”) that was submitted in order to obtain regulatory clearance to market its BGM Galectin-3® Test for a potential new indication for use as an aid...
NASH, a fatty liver disease, has grown in prevalence, with some saying it will replace hepatitis C as the main cause of liver transplantation by 2020.
A mAb-based PET imaging agent targeting
Dr Gabriel Rabinovich meets with ecancertv at AACR 2016 to discuss galectins. In particular, he has worked with Galectin 1 which, when secreted by tumour cells, kills t cells and promotes non-immunogenic tumourous dendritic cell growth. Beyond immune...
BIND Therapeutics, a company developing targeted and programmable therapeutics called ACCURINS, has signed…
Placon Therapeutics, a biotechnology company developing next-generation platinum-based cancer therapies, has launched as an independent company and provided an update on its lead product candidate, BTP-114, for which the FDA has accepted an Investigational New Drug (IND) application to begin clinical evaluation in cancer patients. Placon was spun out from Blend Therapeutics (now Tarveda Therapeuti...
Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptides (Bicycles) platform, has established U.S. operations with headquarters in Cambridge, Massachusetts and named Rosamond Deegan, MBA, as president and chief business officer. In this newly created role, Deegan will be responsible for leading Bicycle Therapeutics’ business ...
An MIT spinout, Synlogic, is aiming to create a new class of medicines, by re-programming bacteria found in the gut as “living therapeutics.”Read more about Living Therapeutics Comments
Tarveda Therapeutics Inc. (formerly Blend Therapeutics) spun out its development-stage platinum-based cancer assets into a new independent entity named Placon Therapeutics.
Regulatory News: Wilson Therapeutics (STO:WTX) The number of shares and votes in Wilson Therapeutics AB (publ) has changed as a result of the new issue of shares that was made in connection with t...
Intensity Therapeutics Inc.'s DfuseRx platform combines known, potent chemotherapeutics with cell-penetration enhancing compounds. The resulting therapeutics are designed to kill tumor cells in masses and then prime the immune system to seek out metastases.
Anglo-Swedish pharma company AstraZeneca will join forces with US biotech firm Moderna Therapeutics to…
// Attractive remuneration package: PsiOxus Therapeutics: PsiOxus Therapeutics Ltd is an Oxford based development stage biotechnology company developing novel therapeutics… Oxfordshire from Job Search RSS http://ift.tt/22q9aVt Cet article #jobs #lifescience PsiOxus Therapeutics: Analytical Development Scientist – Oxfordshire est apparu en premier sur Biotech 365.
STOCKHOLM–(BUSINESS WIRE)–Regulatory News: Wilson Therapeutics (STO:WTX) Wilson Therapeutics AB (publ), announces that the company’s ongoing Phase II clinical trial evaluating the safety and efficacy of Decuprate® (bis-choline tetrathiomolybdate; WTX101) in Wilson Disease patients has been fully enrolled. WTX101-201 is a … Continue reading → Cet article Wilson Th...
Bayer and CRISPR Therapeutics have entered into an agreement to create a joint venture (JV) to discover, develop and commercialize new breakthrough therapeutics to cure blood disorders, blindness, and congenital heart disease. CRISPR Therapeutics will contribute its proprietary CRISPR-Cas9 gene-editing technology and intellectual property, while Bayer will make available its protein engineering ex...